AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immunome Inc. Director's Dealing 2021

Apr 22, 2021

32238_dirs_2021-04-21_3d7938f3-bdca-4b12-aca2-394430a339b4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2021-04-19

Reporting Person: Roche Corleen M. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-19	Stock Option (Right to Buy)	$27.53	A	125000	Acquired	2031-04-19	Common Stock (125000)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on April 19, 2022, and the remaining 75% of shares subject to the option shall vest in equal monthly installments for the 36
months thereafter.